USA flag logo/image

An Official Website of the United States Government

Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / STTR
Agency Tracking Number:
R42HL112518
Solicitation Year:
2012
Solicitation Topic Code:
NHLBI
Solicitation Number:
PA11-097
Small Business Information
Ocean Nano Tech LLC
Springdale, AR 72764-
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor
Agency: HHS
Contract: 1R42HL112518-01
Award Amount: $2,053,613.00
 

Abstract:

DESCRIPTION (provided by applicant): Chest pain in patients presenting to the emergency department (ED) present a clinical dilemma: transfer for emergent coronary revascularization, admit overnight for cardiac telemetry and stress testing, or discharge home with medical follow-up. In this proposal, we hypothesize that a novel thrombus-specific Spectral Computed Tomography (Multicolored CT) nanoparticle (i.e., NanoK) approach for direct rapid assessment of coronary disease in the ED could help resolve this clinical dilemma. This project, which is led by Ocean NanoTech in collaboration with Washington University, will complete development of a GLP-/GMP-ready 1- fibrin NanoK product candidate suitably advanced for GLP stability and toxicity testing to support an FDA IND. This NanoK platform technology offers unique benefits for diagnosis and treatment of acute coronary disease that could improve healthcare outcomes and reduce costs. PUBLIC HEALTH RELEVANCE: Chest pain in patients presenting to the emergency department (ED) present a clinical dilemma: transfer for emergent coronary revascularization, admit overnight for cardiac telemetry and stress testing, or discharge home with medical follow-up. While the emergent need for cardiac catheterization is selfevident from the presentation of some individuals, the determination of whether to admit or discharge a patient with an equivocal history and physical is often problematic. In lieu of missing a critical cardiac diagnosis, patients are admitted for myocardial evaluation and stress testing, which is inconvenient, costly and unnecessary in the majority of cases. In this proposal, we hypothesize that a novel thrombus-specific Spectral Computed Tomography (Multicolored CT) nanoparticle (i.e., NanoK) approach for direct rapid assessment of coronary disease in the ED could help resolve this clinical dilemma. This project describes the demonstration of the prototype concept in Phase 1 and the development, demonstration, and characterization of the clinical productcandidate in Phase II. The overarching goal of this project, which is led by Ocean NanoTech in collaboration with Washington University, will be to complete development of a GLP- /GMP-ready 1-fibrin NanoK product candidate suitably advanced for GLP stability and toxicity testing to support an FDA IND. This NanoK platform technology offers unique benefits for diagnosis and treatment of acute coronary disease that could improve healthcare outcomes and reduce costs.

Principal Investigator:

Y. A. Wang
479-751-5500
awang@oceannanotech.com

Business Contact:

Alice M. Bu
479-751-5500
alicebu@oceannanotech.com
Small Business Information at Submission:

OCEAN NANOTECH, LLC
2143 Worth Lane SPRINGDALE, AR 72764-

EIN/Tax ID: 127009756
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF WASHINGTON
UNIVERSITY OF WASHINGTON
Office of Sponsored Programs 4333 Brooklyn Ave NE Box 359472
SEATTLE, WA 98195-9472
Contact: